Evidence map›Paper›PMID 41922688›Full record

ArticleNPJ precision oncology2026

Neoadjuvant mFOLFOX6 plus camrelizumab and apatinib in colon cancer and biomarker research via spatiotemporal-omics profiling.

Zhou Tong, Liaoliao Gao, Danyang Wang, Peng Zhao, Xuanwen Bao, Hangyu Zhang, Xiaomeng Dai, Lulu Liu, Xudong Zhu, Yang Gao and 6 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04625803 (Camrelizumab and Apatinib Combined With Chemotherapy), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04625803 phase2completednot on this map

Camrelizumab and Apatinib Combined With Chemotherapy (mFOLFOX6) in Neoadjuvant Therapy for Locally Advanced Colon Cancer

TypeinterventionalSponsorZhejiang UniversityRan2021 to 2023Enrolled64ConditionsColon Cancer, Neoadjuvant TherapyArmsCamrelizumab , apatinib and chemotherapy
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Zhou Tong *Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Liaoliao Gao *School of medicine, Zhejiang University, Hangzhou, China.
Danyang Wang *Department of colorectal surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Peng Zhao *Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xuanwen BaoDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Hangyu ZhangDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xiaomeng DaiDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Lulu LiuDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xudong ZhuDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yang GaoDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yi ZhengDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Qihan FuDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Fanlong LiuDepartment of colorectal surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. fanlong_liu@zju.edu.cn.
Wenbin ChenDepartment of colorectal surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. wenbinchen@zju.edu.cn.
Xiangming XuDepartment of Colorectal Surgery and Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. xuxiangming@zju.edu.cn.
Weijia FangDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. weijiafang@zju.edu.cn.

Funding

Beijing Xisike Clinical Oncology Research Foundation Y-NESTLE2022QN-0345National Natural Science Foundation of China 82203186National Natural Science Foundation of China 82373428Noncommunicable Chronic Diseases-National Science and Technology Major Project 2023ZD0501600The "Pioneer" and "Leading Goose" R&D Program of Zhejiang 2025C02073
6 · The paper itself

Abstract

This is a single-arm, phase II clinical trial aimed to evaluate mFOLFOX6 plus camrelizumab and apatinib as a neoadjuvant regimen for locally advanced colon cancer. This trial was registered on ClinicalTrials.gov (NCT04625803), with the registration date of November 30, 2020. The primary endpoint was the pathological response rate (TRG 2-4, Dworak criteria). Time-of-flight, imaging mass cytometry and spatial proteomic analysis was applied to explore efficacy-related predictive biomarkers. Of 12 enrolled patients, 11 underwent surgery. The TRG 2-4 rate was 81.8% overall (87.5% in the MSS subgroup). Five patients (45.5%) achieved pathological complete response (pCR). With a median follow-up of 36.60 months, only one patient relapsed. An increase in the frequency of CD8

Identifiers

PMID41922688
PMCPMC13212963

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.